CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immage Biotherapeutics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immage Biotherapeutics Corp
10411 Motor City Dr Ste 750
Phone: (443) 961-1185p:443 961-1185 BETHESDA, MD  20817-1289  United States Ticker: IMMGIMMG
This company ceased filing statements with the SEC on 6/21/2017.
Business Summary
Immage Biotherapeutics Corp. is a biotechnology company. The Company is engaged in developing cancer immunotherapy through development of cutting-edge immunotherapy candidates using bioinformatics and outsourced laboratory resources. It is focused on developing immunotherapy biologics to treat various cancers. The Company develops, markets and licenses its immunotherapy candidate for melanoma-associated antigen-A (MAGE A). The Company plans to focus on the development of immunotherapy for breast and prostate cancer. The Company focuses on developing a fusion/hybrid antigen cancer vaccine that would not only be human leukocyte antigen (HLA) free, but also be effective to all the isomers associated with MAGE A, from 1 to 11, and the identification and development of immunotherapy candidates from its intellectual property library for the preparation for human clinical trials using a viral vector construct.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
2/28/20178/31/2016YesYes---

Industries
SIC Code Description
2865 Cyclic organic crudes and intermediates, and organic dyes and pigments

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Scientific Officer AntonDormer 7/24/2015 7/24/2015
President, Chief Executive Officer, Treasurer, Secretary, Director Zhi CongMou 32 7/24/2015 4/7/2015
Chief Financial Officer, Director Elton F.Norman 7/24/2015 7/24/2015
Chief Operating Officer, Director MaheshNarayanan 7/24/2015 7/24/2015
Vice President - Bioformatics DanielAchinko 7/24/2015 7/24/2015

General Information
Outstanding Shares: 151,744,566 (As of 4/3/2017)
Stock Exchange: OTC
Federal Tax Id: 455538945


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023